Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre‐eclampsia in women with chronic hypertension

Abstract

ABSTRACTObjectiveTo compare the predictive performance for delivery with pre‐eclampsia (PE) within 2 weeks of assessment in women with chronic hypertension at 24–41 weeks' gestation between serum glycosylated fibronectin (GlyFn) concentration, serum placental growth factor (PlGF) concentration and soluble fms‐like tyrosine kinase‐1 (sFlt‐1) to PlGF concentration ratio.MethodsThis was a prospective study of 104 women with a singleton pregnancy and chronic hypertension presenting at 24–41 weeks' gestation. Twenty‐six (25.0%) cases developed superimposed PE within 2 weeks of sampling. We compared the predictive performance for superimposed PE between GlyFn, PlGF and the sFlt‐1/PlGF ratio at a fixed screen‐positive rate of approximately 10%.ResultsThe median gestational age at sampling was 34.1 (interquartile range, 31.5–35.6) weeks and 84.6% (88/104) of cases were sampled at < 36 weeks. The predictive performance for superimposed PE of the three methods of screening was similar, with detection rates of about 23–27%, at a screen‐positive rate of 11% and a false‐positive rate of about 5%.ConclusionsMeasurement of GlyFn is a simple point‐of‐care test that can be carried out without need for a laboratory and provide results within 10 min of testing. In this respect, it could potentially replace the angiogenic markers that are used currently in the prediction of imminent PE in high‐risk women. However, neither GlyFn nor angiogenic factors are likely to improve the management of women with chronic hypertension because their predictive performance for superimposed PE is poor. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.